Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP1189 add-on versus placebo in idiopathic membranous nephropathy with severe proteinuria
2024-518384-36-00Phase 2Authorised
- Sponsor
- SynAct Pharma AB
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in idiopathic membranous glomerulonephritis (IMG) comparing RESOMELAGON add-on with Placebo add-on (2 arms). Primary endpoints: Safety and Change in 24-hour urinary protein excretion. Planned start Oct 2024; status: authorised.
02
Drugs
resomelagon
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on 2024-518384-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518384-36-00.